SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2005

ISOTIS S.A.

(Exact name of registrant as specified in its charter)

1 Rue de Sébeillon,

1004, Lausanne

Switzerland

(Address of Principal Executive Offices)

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

Form 20-F

Form 40-F

(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)

Yes

(If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b).)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

July 13, 2005
IsoTis S.A.

	By	/s/ ROBERT J. MOROCCO

	Name:	Robert J. Morocco
	Title:	Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description

99.1		Press Release: IsoTis OrthoBiologics Receives FDA 510(k) Clearance for Accell Connexus(TM)

IsoTis OrthoBiologics Receives FDA 510(k) Clearance for Accell Connexus(TM)

LAUSANNE, Switzerland, IRVINE, CA, USA – July 13, 2005 - IsoTis OrthoBiologics (SWX/Euronext: ISON; TSX: ISO) today announced it received 510(k) clearance from the US Food and Drug Administration (FDA) for Accell Connexus(TM) (“Connexus”) for orthopedic applications.

Connexus is an osteoinductive demineralized bone matrix (DBM) putty that provides exceptional handling and graft containment. It is part of the Company’s proprietary Accell(R) technology product line along with Accell(R) DBM100 putty and Accell Total Bone Matrix (TM) pre-formed DBM. Connexus is a DBM putty with an array of growth factors, including TGF- ß1 and a cocktail of natural human bone morphogenetic proteins (nhBMPs™). Compared to 1^st generation DBM products, the AccellRx process on which Connexus is based yields a higher level of TGF- ß1 and nhBMPs, including BMP-2, BMP-4 and BMP-7, which act synergistically to stimulate new bone formation. Employing a state-of-the-art reverse phase carrier, Connexus thickens at body temperature and resists irrigation so the nhBMPs are delivered at the surgical site where they are needed.

IsoTis OrthoBiologics has a product portfolio with several innovative and proprietary natural and synthetic bone graft substitutes on the market and others in development, orthobiology sales of over US$ 25 million in 2004, an established North American independent distribution network, and an expanding international presence. The company’s main commercial operations are based out of Irvine, CA; its international sales headquarters is based in Lausanne, Switzerland.

For information contact:
Hans Herklots
Tel: +41(0)21 620 6011
Fax: +41 (0)21 620 6060
E-mail: hans.herklots@isotis.com

Certain statements in this Press Release are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Words such as ‘strategy,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘will,’ ‘continues,’ ‘estimates,’ ‘intends,’ ‘projects,’ ‘goals,’ ‘targets’ and other words of similar meaning are intended to identify such forward-looking statements. One can also identify them by the fact that they do not relate strictly to historical or current facts. Such statements are based on the current expectations of the management of IsoTis S.A. only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of IsoTis. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting IsoTis’ business, including but not limited to the timely commencement and success of IsoTis’ clinical trials and research endeavors, delays in receiving U.S. FDA or other regulatory approvals (a.o. EMEA, CE), market acceptance of the Company’s products, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet conditions imposed for the required governmental and regulatory approvals and consents. IsoTis expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting IsoTis, refer to the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2004, filed with the SEC and to IsoTis’ reports filed from time to time with the Swiss Stock Exchange (SWX), Euronext Amsterdam N.V., and SEDAR at www.sedar.com, as well as the Toronto Stock Exchange (TSX).

ISOTIS SA 6-K